TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03437694

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication optimization intervention
Description: Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication optimization intervention
Description: Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
Study: NCT01868971

Intervention type: DEVICE
Group type: OTHER
Intervention: EndoRings
Description: Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician's evaluation
Study: NCT00479258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (Exubera)
Description: Inhaled insulin with dose adjusted according to premeal blood glucose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin (subject's prescribed)
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study: NCT00175058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AO Therapy (aqueous oxygen)
Description: 90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
Study: NCT02017717

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: specified dose on specified days
Study: NCT01707134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected subcutaneously (s.c, under the skin) as meal time insulin
Study: NCT04120922

Intervention type: OTHER
Group type: OTHER
Intervention: calcium carbonate
Description: See arm description

Intervention type: OTHER
Group type: OTHER
Intervention: sevelamer carbonate
Description: See arm description

Intervention type: OTHER
Group type: OTHER
Intervention: sevelamer carbonate
Description: See arm description
Study: NCT01989130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Roche AMPLICOR CT/NG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cepheid Xpert CT/NG Test
Study: NCT02738671

Intervention type: OTHER
Intervention: olfactory function measurement

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: Only a subgroup of the subjects will have the bariatric surgery.
Study: NCT03990870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dCBGT + WASABI
Description: Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dCBGT Only
Description: Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
Study: NCT00705978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin
Description: Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01214486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
Study: NCT03908944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
Study: NCT03567148

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: Applying to the palatal wounds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Essix retainer
Description: Applying to the palatal wounds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Applying to the palatal wounds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT
Description: Applying to the palatal wounds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen fleece
Description: Applying to the palatal wounds
Study: NCT00789633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib at 9 mg/kg/day given orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m2 by intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine at 1000 mg/m2 by intravenous infusion
Study: NCT00358657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic bone marrow transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total-body irradiation
Study: NCT01940484

Intervention type: DRUG
Intervention: Methoxy polyethylene glycol epoetin beta
Study: NCT00967265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introduction seminar
Description: The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT03320499

Intervention type: PROCEDURE
Intervention: echo doppler at the bed
Description: we practise the echo doppler at the patient 's bed

Intervention type: PROCEDURE
Intervention: echo doppler in the vascular exploration platform
Description: as usual , practising echo doppler in the medical platform
Study: NCT01196442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation pain therapy
Description: Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
Study: NCT04139083

Intervention type: PROCEDURE
Intervention: LSC mesh suspension
Description: Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.

Intervention type: PROCEDURE
Intervention: TVM
Description: Transvaginal mesh kit is delivered into the pelvis via vagina route.
Study: NCT02138734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )
Description: BCG and N-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+N-803 for 3 consecutive weeks at 3, 6, 12, 18, 24,30 and 36 months.~An additional 6 week re-induction of BCG+N-803 for patients with eligible disease at 3 months in phase IIb is included.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG( 50mg/Instillation)
Description: BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, 18, 24, 30 and 36 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included.
Study: NCT04668508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
Study: NCT01705691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV over 60 minutes weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
Study: NCT04232826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
Study: NCT03311971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Patients will be treated with virtual glasses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No VR glasses
Description: Patients will not use VR glasses
Study: NCT01290926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: sorafenib 600mg/day capecitabine 1250 mg/m²/day
Study: NCT02581995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: 2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
Study: NCT01707134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human soluble insulin
Description: Injected subcutaneously (s.c, under the skin) as meal time insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
Study: NCT02204904

Intervention type: GENETIC
Intervention: Allo-HSCT
Description: Allogeneic Hematopoietic Stem Cell Transplantation

Intervention type: GENETIC
Intervention: Allo-HSCT
Description: Allogeneic Hematopoietic Stem Cell Transplantation

Intervention type: GENETIC
Intervention: Allo-HSCT
Description: Allogeneic Hematopoietic Stem Cell Transplantation
Study: NCT01113320

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide
Description: Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
Study: NCT00849017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide uptitration
Description: albiglutide uptitration at week 12

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching albiglutide placebo weekly injection
Study: NCT00802815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 milligrams subcutaneously every week
Study: NCT00484744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT03502187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Exercise Plan
Description: The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about \~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
Study: NCT01707134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
Study: NCT01434147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
Description: Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
Study: NCT03502187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuromuscularElectricalStimulation(NMES)
Description: The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back \& abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Management (PCM)
Description: All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
Study: NCT00318383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX conjugate vaccine
Description: 200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX conjugate vaccine
Description: 200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX conjugate vaccine
Description: 200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
Study: NCT00484744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avicel (placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study: NCT02744950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulley stitches

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate Repair
Study: NCT01147133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix
Description: 1x75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kardogrel
Description: 1x75 mg
Study: NCT00318383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX conjugate vaccine
Description: 200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX conjugate vaccine
Description: 200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
Study: NCT02514941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talinolol
Description: Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talinolol
Description: Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talinolol
Description: Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water